Next Article in Journal
Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis
Previous Article in Journal
Solubility Improvement of Benexate through Salt Formation Using Artificial Sweetener
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Pharmaceutics 2018, 10(2), 65; https://doi.org/10.3390/pharmaceutics10020065

Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers

Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, 47500 Petaling Jaya, Selangor, Malaysia
*
Author to whom correspondence should be addressed.
Received: 6 April 2018 / Revised: 19 May 2018 / Accepted: 22 May 2018 / Published: 26 May 2018
Full-Text   |   PDF [2448 KB, uploaded 26 May 2018]   |  

Abstract

RNA Interference (RNAi) has brought revolutionary transformations in cancer management in the past two decades. RNAi-based therapeutics including siRNA and shRNA have immense scope to silence the expression of mutant cancer genes specifically in a therapeutic context. Although tremendous progress has been made to establish catalytic RNA as a new class of biologics for cancer management, a lot of extracellular and intracellular barriers still pose a long-lasting challenge on the way to clinical approval. A series of chemically suitable, safe and effective viral and non-viral carriers have emerged to overcome physiological barriers and ensure targeted delivery of RNAi. The newly invented carriers, delivery techniques and gene editing technology made current treatment protocols stronger to fight cancer. This review has provided a platform about the chronicle of siRNA development and challenges of RNAi therapeutics for laboratory to bedside translation focusing on recent advancement in siRNA delivery vehicles with their limitations. Furthermore, an overview of several animal model studies of siRNA- or shRNA-based cancer gene therapy over the past 15 years has been presented, highlighting the roles of genes in multiple cancers, pharmacokinetic parameters and critical evaluation. The review concludes with a future direction for the development of catalytic RNA vehicles and design strategies to make RNAi-based cancer gene therapy more promising to surmount cancer gene delivery challenges. View Full-Text
Keywords: RNA interference; small interfering RNA (siRNA); short hairpin RNA (shRNA); viral and non-viral carriers; cancer; gene therapy RNA interference; small interfering RNA (siRNA); short hairpin RNA (shRNA); viral and non-viral carriers; cancer; gene therapy
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Karim, M.E.; Tha, K.K.; Othman, I.; Borhan Uddin, M.; Chowdhury, E.H. Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers. Pharmaceutics 2018, 10, 65.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top